Vanguard Group Inc. Purchases 531,162 Shares of Amylyx Pharmaceuticals, Inc. $AMLX

Vanguard Group Inc. grew its position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) by 10.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,804,912 shares of the company’s stock after purchasing an additional 531,162 shares during the quarter. Vanguard Group Inc. owned approximately 5.29% of Amylyx Pharmaceuticals worth $70,123,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the company. China Universal Asset Management Co. Ltd. raised its position in shares of Amylyx Pharmaceuticals by 14.5% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 17,895 shares of the company’s stock valued at $216,000 after purchasing an additional 2,265 shares during the period. Arizona State Retirement System acquired a new position in shares of Amylyx Pharmaceuticals during the 4th quarter worth about $277,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Amylyx Pharmaceuticals by 1,782.3% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 35,877 shares of the company’s stock worth $433,000 after purchasing an additional 33,971 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Amylyx Pharmaceuticals by 54.8% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,337 shares of the company’s stock worth $64,000 after purchasing an additional 1,890 shares during the last quarter. Finally, SG Americas Securities LLC lifted its position in shares of Amylyx Pharmaceuticals by 76.4% during the 4th quarter. SG Americas Securities LLC now owns 20,846 shares of the company’s stock worth $252,000 after purchasing an additional 9,027 shares during the last quarter. Institutional investors own 95.84% of the company’s stock.

Amylyx Pharmaceuticals Stock Down 4.8%

Shares of AMLX opened at $13.88 on Friday. Amylyx Pharmaceuticals, Inc. has a 12-month low of $4.26 and a 12-month high of $18.60. The firm has a market capitalization of $1.54 billion, a price-to-earnings ratio of -9.25 and a beta of -0.11. The stock’s 50-day moving average price is $15.32 and its 200 day moving average price is $14.25.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.03). Equities research analysts expect that Amylyx Pharmaceuticals, Inc. will post -1.39 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on AMLX. HC Wainwright reissued a “buy” rating and set a $34.00 price objective on shares of Amylyx Pharmaceuticals in a research report on Wednesday, March 25th. Guggenheim boosted their price objective on Amylyx Pharmaceuticals from $25.00 to $30.00 and gave the stock a “buy” rating in a research report on Thursday, March 19th. Mizuho boosted their price objective on Amylyx Pharmaceuticals from $19.00 to $21.00 and gave the stock an “outperform” rating in a research report on Tuesday, April 28th. Wall Street Zen cut Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Finally, Stifel Nicolaus began coverage on Amylyx Pharmaceuticals in a research report on Tuesday, March 3rd. They set a “buy” rating and a $21.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $23.00.

More Amylyx Pharmaceuticals News

Here are the key news stories impacting Amylyx Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright kept a Buy rating on Amylyx Pharmaceuticals and maintained a $34 price target, signaling continued confidence in the stock’s upside.
• Positive Sentiment: The firm slightly increased its Q2 2026, Q3 2026 and Q4 2026 EPS estimates, which suggests modestly better expectations for near-term performance.
• Positive Sentiment: Amylyx also presented at the Bank of America Global Healthcare Conference, which can keep investor focus on the company’s strategy and pipeline. Article Title
• Neutral Sentiment: HC Wainwright lowered some longer-term earnings estimates for FY2027 through FY2030, reflecting a more mixed outlook beyond the next few years.
• Neutral Sentiment: The analyst revisions were mostly small, so they are more of a fine-tuning of forecasts than a major change in the investment thesis.

Amylyx Pharmaceuticals Profile

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.